Skip to main content

Table 1 Model Inputs for the patient characteristics and cost

From: Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda

Input Value Sensitivity Range Source Data
Life Expectancy, in years     
CD4 = 50-200 9.60 8.16 11.04 [19]
CD4 = 200-350 19.30 16.41 22.20 [19]
CD4 tests per year 2    [20]
Median CD4 cell decline, per 6 months 45.75 30.65 62.35 [21]
DALY Adjustmenta     
HIV 0.123    [22]
AIDS 0.5    [22]
Years of AIDS before death 1    Assumption
Annual Number of Inpatient Days with OIb,c     
CD4 > 350 (on cART) 0.37 0.19 0.56 [23]
CD4 > 350 (off cART) 5.7 2.85 8.55 [23]
CD4 = 201-350 (on cART) 0.52 0.26 0.78 [23]
CD4 = 201-350 (off cART) 10.8 5.4 16.2 [23]
Annual Number of Inpatient Days without OIb,c     
CD4 > 350 (on cART) 0.14 0.07 0.21 [23]
CD4 > 350 (off cART) 1.9 0.95 2.85 [23]
CD4 = 201-350 (on cART) 0.39 0.2 0.59 [23]
CD4 = 201-350 (off cART) 3 1.5 4.5 [23]
Costs     
cART drug cost, per yeard $192.44 $100 $300 [24]
cART maintenance cost, year $113.40 $50 $200 [25]
Total Treatment cost, sum $305.84 $150 $500 [24, 25]
Annual costs incurred while waiting     
Clinic Personel $14.32    [25]
Lab $35.04    [25]
Other Medication $33.72    [25]
Radiology $1.68    [25]
Sum $84.76 $0 $150 [25]
Cost per Inpatient Day $31.48    [26]
Discount Rate 3% 0% 6% [18]
  1. aDALY - Disability Adjusted Life Years.
  2. b OI – Opportunistic infections.
  3. c The sensitivity range is not reported in[23]. In our model, we assume a 50% decrease and 50% increase in OI’s relative to the base case.
  4. dcART- combination antiretroviral therapy, containing: AZT – zidovudine ; 3TC – lamivudine; EFV- efavirenz.